GSK, Google parent forge £540m bioelectronic medicines firm
Tie-up will develop miniaturised, implantable devices that can modify electrical nerve signals
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
London
GLAXOSMITHKLINE (GSK) and Google parent Alphabet's life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics.The tie-up shows the growing convergence of health care and technology.
Verily Life Sciences - known as Google's life sciences unit until last year - and Britain's biggest drugmaker will together contribute £540 million (S$953.9 million) over seven years to Galvani Bioelectronics, they said on Monday.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
